Having invested $84 million almost a year and a half ago to launch a drug discovery collaboration with GeneProt, Novartis might not seem the most likely big pharma candidate to establish a strong and growing internal proteomics research program of its own. After all, the deal with GeneProt is still most likely the largest of its kind, dwarfing Oxford GlycoScience’s cumulative $22.5 million deal with Pfizer, and represents a massive capital and human resource investment for GeneProt’s 110 Geneva-based employees.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.